Australian insurer Challenger rejects a takeover offer from Daiichi Life’s Australian unit, according to reports. Daiichi Life’s subsidiary proposed buying the remaining 79.5% of Challenger at 11.80 Australian dollars per share.

Both outlets describe the offer and Challenger’s response, focusing on the corporate move and the share-price terms rather than broader industry impacts. The coverage differs mainly in emphasis and wording: Nikkei Asia leads with Challenger’s rejection, while Japan Times highlights the $4.4 billion valuation of the bid alongside the deal structure.

No further outcomes, negotiations, or regulatory steps are detailed in the provided summaries.